Application of ACEI/ARB is one of the major concerns in treating COVID-19 among patients with hypertension, for the possible increased risk by ACEI/ARB on increased ACE2, a direct receptor and entry point of severe acute respiratory syndrome coronavirus 2. Here, ACE2 is linked to hypertensive disorder.